April 2011
Volume 52, Issue 14
Free
ARVO Annual Meeting Abstract  |   April 2011
Study of Polyhexamethylene Biguanide and Calcineurin Inhibitors for the Treatment of Aspergillus Keratitis in a Murine Model
Author Affiliations & Notes
  • Natalie A. Afshari
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • Rachelle A. Rebong
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • Ricardo M. Santaella
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • Christopher P. Majka
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • Brian E. Goldhagen
    Ophthalmology, Duke University Eye Center, Durham, North Carolina
  • William J. Steinbach
    Pediatric Infectious Diseases, Duke University Medical Center, Durham, North Carolina
  • Footnotes
    Commercial Relationships  Natalie A. Afshari, None; Rachelle A. Rebong, None; Ricardo M. Santaella, None; Christopher P. Majka, None; Brian E. Goldhagen, None; William J. Steinbach, None
  • Footnotes
    Support  Allergan Horizon Grant, Research to Prevent Blindness
Investigative Ophthalmology & Visual Science April 2011, Vol.52, 2934. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Natalie A. Afshari, Rachelle A. Rebong, Ricardo M. Santaella, Christopher P. Majka, Brian E. Goldhagen, William J. Steinbach; Study of Polyhexamethylene Biguanide and Calcineurin Inhibitors for the Treatment of Aspergillus Keratitis in a Murine Model. Invest. Ophthalmol. Vis. Sci. 2011;52(14):2934.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: : To establish a novel mouse model of Aspergillus keratitis and to assess the ability of the calcineurin-inhibitor cyclosporin A (CsA) to work synergistically with voriconazole (VCZ), amphotericin B (AMB), and polyhexamethylene biguanide (PHMB) against Aspergillus keratitis in vivo.

Methods: : The corneas of BALB/c mice were scarred and then inoculated with wild type A. fumigatus to produce infection. An ophthalmologist masked to the treatment groups assessed disease severity daily based on a grading scale from 0 (no disease) to 4 (severe disease). Infected mice were randomly assigned to groups being treated with saline (control), AMB, VCZ, PHMB, CSA, VCZ+CSA, AMB+CSA, or PHMB+CSA. The mean change in disease score between groups was compared using an analysis of variance and the Student's t-test.

Results: : A novel murine model of Aspergillus keratitis was established with a 65% infection rate. The mean end change in disease score per group were as follows (mean end change ± SD): saline -1.08 ± 1.08, AMB -1.84 ± 1.28, AMB+CSA -1.11 ± 1.12, VCZ -1.53 ± 0.78, VCZ+CSA -0.42 ± 1.22, PHMB -0.96 ± 1.27, and PHMB+CSA -1.39 ± 1.16. Although all treatment groups showed significant disease improvement compared to the control group (p < 0.05), pairwise comparisons between treatment groups were not significant.

Conclusions: : A novel murine model of Aspergillus keratitis was established. PHMB is effective in treating Aspergillus keratitis in vivo. The use of calcineurin inhibitors to treat Aspergillus keratitis warrants further investigation.

Keywords: fungal disease • cornea: basic science 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×